Anatara Lifesciences Ltd (AU:ANR) — Market Cap & Net Worth
Market Cap & Net Worth: Anatara Lifesciences Ltd (ANR)
Anatara Lifesciences Ltd (AU:ANR) has a market capitalization of $1.57 Million (AU$2.23 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #29894 globally and #1772 in its home market, demonstrating a -10.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anatara Lifesciences Ltd's stock price AU$0.01 by its total outstanding shares 247237922 (247.24 Million). Analyse cash flow conversion of Anatara Lifesciences Ltd to see how efficiently the company converts income to cash.
Anatara Lifesciences Ltd Market Cap History: 2015 to 2026
Anatara Lifesciences Ltd's market capitalization history from 2015 to 2026. Data shows change from $164.67 Million to $1.57 Million (-35.56% CAGR).
Anatara Lifesciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anatara Lifesciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.53x
Anatara Lifesciences Ltd's market cap is 2.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $167.05 Million | $2.45 Million | -$723.93K | 68.23x | N/A |
| 2017 | $275.23 Million | $2.85 Million | -$1.71 Million | 96.44x | N/A |
| 2018 | $73.18 Million | $6.47K | -$3.57 Million | 11315.29x | N/A |
| 2019 | $38.19 Million | $663.40K | -$2.87 Million | 57.56x | N/A |
| 2024 | $8.22 Million | $644.03K | -$1.45 Million | 12.77x | N/A |
| 2025 | $2.45 Million | $969.46K | -$1.95 Million | 2.53x | N/A |
Competitor Companies of ANR by Market Capitalization
Companies near Anatara Lifesciences Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Anatara Lifesciences Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Anatara Lifesciences Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Anatara Lifesciences Ltd's market cap moved from $164.67 Million to $ 1.57 Million, with a yearly change of -35.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$1.57 Million | -35.71% |
| 2025 | AU$2.45 Million | -70.21% |
| 2024 | AU$8.22 Million | +113.64% |
| 2023 | AU$3.85 Million | -31.03% |
| 2022 | AU$5.58 Million | -74.94% |
| 2021 | AU$22.27 Million | -17.66% |
| 2020 | AU$27.05 Million | -29.18% |
| 2019 | AU$38.19 Million | -47.81% |
| 2018 | AU$73.18 Million | -73.41% |
| 2017 | AU$275.23 Million | +64.76% |
| 2016 | AU$167.05 Million | +1.44% |
| 2015 | AU$164.67 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Anatara Lifesciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.57 Million USD |
| MoneyControl | $1.57 Million USD |
| MarketWatch | $1.57 Million USD |
| marketcap.company | $1.57 Million USD |
| Reuters | $1.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more